PMH4 A PHASE IV STUDY OF THE EFFECTIVENESS OF QUETIAPINE EXTENDED RELEASE 600 MG ONCE A DAY TO CONTROL THE SYMPTOMS OF MANIC PHASE OF BIPOLAR DISORDER:THE EMMY TRIAL  by Segovia, M et al.
13th Euro Abstracts A445
a broader understanding of the inﬂ uence of epidemics on health care systems. It is 
possible to investigate feedback of health service structure changes and reimbursement 
decisions on prevalence and effects of infectious diseases.
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IS IT POSSIBLE TO OBTAIN WILLINGNESS-TO-PAY ESTIMATES IN 
EUROPE? A VALIDITY TEST OF STATED PREFERENCES FOR 
HEPATITIS-B TREATMENTS
Johnson FR1, Mohamed A1, Hauber AB1, Lescrauwaet B2
1RTI Health Solutions, Research Triangle Park, NC, USA; 2Bristol-Myers Squibb, 
Braine—L’Alleud, Belgium
BACKGROUND: Because health care is highly insured in Europe, many discrete-
choice experiment (DCE) researchers have concerns about the feasibility of obtaining 
valid willingness-to-pay (WTP) estimates. OBJECTIVES: To test the validity of WTP 
estimates obtained from patient DCE data in 5 countries. METHODS: Adults with a 
self-reported physician diagnosis of hepatitis B in 4 European countries (France, 
Germany, Spain, and Italy) and Turkey completed a web-enabled, DCE. The survey 
presented patients with a series of 12 trade-off questions, each including a pair of 
hypothetical hepatitis-B treatments described by efﬁ cacy, two side-effect risks, weight 
of evidence, and cost. All the subjects saw cost levels of c0, c10, and c25. Half the 
subjects evaluated an additional cost level of c75 and half the subjects evaluated an 
additional cost level of c150 per month. RESULTS: 664 subjects completed the survey. 
About 15% of subjects refused to accept any tradeoffs between costs and outcome 
attributes, while the remainder perceived no signiﬁ cant difference between costs of c0 
and c10. The difference in importance weights between the highest cost levels in each 
treatment arm was signiﬁ cantly different (P < 0.000). The importance weight of one 
additional euro in cost of c25 or greater was negative, highly signiﬁ cant, and equal 
in both arms (p = <0.000). Compared to a treatment with 70% probability of achiev-
ing no detectable virus after 5 years and no side-effect risk, the increase in value to 
patients of a hypothetical treatment that has 95% effectiveness, 1% 5-year fracture 
risk, and 1% 5-year risk of kidney disease is an additional c34 (c17–c51) per month. 
CONCLUSIONS: We obtained DCE responses in a split-sample test of cost sensitivity 
that were consistent with theoretical requirements. Results suggest that it is possible 
to obtain valid WTP estimates in a properly motivated European DCE. 
MENTAL HEALTH – Clinical Outcomes Studies
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THE EFFICACY OF DONEPEZIL AND MEMANTINE FOR TREATING 
BEHAVIOURAL AND PSYCHOLOGICAL SYMPTOMS OF DEMENTIA 
(BPSD) IN PATIENTS WITH ALZHEIMER’S DISEASE: SYSTEMATIC 
REVIEW AND META-ANALYSIS
Orme M1, Mitchell S2, Lockhart I3, Collins S2
1ICERA consulting Ltd, Swindon, Wiltshire, UK; 2Abacus International, Bicester, Oxfordshire, 
UK; 3Pﬁ zer Limited, Tadworth, Surrey, UK
OBJECTIVES: Behavioral and psychological symptoms of dementia (BPSD) in 
Alzheimer’s disease (AD) greatly increase caregiver burden and often trigger nursing 
home placement. a systematic review of double-blind randomized controlled trials 
(RCTs) was conducted to compare the ability of donepezil and memantine to manage 
BPSD in AD. METHODS: MEDLINE, EMBASE, Cochrane Library, and hand 
searches identiﬁ ed 4739 citations, of which 16 studies had Neuropsychiatric Inventory 
(NPI) data suitable for meta-analysis (6 memantine and ten donepezil trials). All trials 
were placebo-controlled, and no head-to-head comparisons of the two drugs were 
identiﬁ ed. a random-effects meta-analysis was conducted using AD severity subgroups 
to investigate heterogeneity between trials. Thereafter meta-regression was conducted 
using study level covariates as potential predictors of between-treatment weighted 
mean difference (WMD) in NPI score. RESULTS: Unadjusted random effects meta-
analysis of all 16 RCTs found signiﬁ cant between-study heterogeneity (all studies I2 = 
64.4%; donepezil vs. placebo WMD −1.84, 95%CI −3.57, −0.10, I2 = 61%; meman-
tine monotherapy vs. placebo WMD −1.19, 95% CI −3.70, 1.32, I2 = 68.7%; meman-
tine + AChEI combination therapy vs. placebo WMD −1.68 95% CI −5.70, 2.33, I2 
= 80.4%). Meta-regression that stratiﬁ ed studies into four AD severity groups mea-
sured by Mini-Mental State Exam (MMSE) (severe 0–9, moderately-severe 10–14, 
moderate 15–20 and mild 21–26) and controlling for age at baseline, found these 
covariates accounted for most (59.85%) of the between-study variance. Using this 
meta-regression model, the pooled NPI score for donepezil showed signiﬁ cant 
improvement compared to placebo (MD −1.50; 95% CI −2.63, −0.36) whereas this 
was not the case for memantine vs. placebo (MD −1.25; 95% CI −2.63, 0.13). CON-
CLUSIONS: Donepezil was associated with signiﬁ cant improvement in the manage-
ment of BPSD in AD patients compared to placebo, whereas memantine failed to show 
a signiﬁ cant improvement versus placebo in the management of these symptoms.
PMH2
COMPARING ALL-CAUSE MEDICATION DISCONTINUATION WITH 
DEPOT AND ORAL ANTIPSYCHOTICS IN MATCHED COHORTS OF 
PATIENTS WITH SCHIZOPHRENIA: A 12-MONTH OBSERVATIONAL 
STUDY
Brnabic AJ1, Kelin K1, Ascher-Svanum H2, Kadziola Z3, Montgomery W4
1Eli Lilly & Company, Sydney, NSW, Australia; 2Eli Lilly & Company, Indianapolis, IN, USA; 
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OBJECTIVES: To assess the all-cause medication discontinuation rate in matched 
cohorts of patients with schizophrenia at risk of nonadherence who were initiated on 
depot or oral antipsychotics and followed over 12 months. METHODS: At study 
entry, outpatients with schizophrenia from Australia, Mexico, Romania, and Taiwan 
were switched, due to clinician-perceived medication non-adherence risk, from their 
current oral antipsychotic to either a depot or different oral antipsychotic in this 
12-month, prospective observational study. Patients were compared on all-cause medi-
cation discontinuation rates, deﬁ ned as a switch from the initiated medication or its 
augmentation with another antipsychotic. Patients initiated on depot were matched 
with those initiated on any oral antipsychotic, using full optimal and nearest neighbour 
(greedy) matching algorithms. The Rank-based Mahalanobis metric was chosen as the 
distance based on propensity score plus other relevant covariates, with country and 
antipsychotic class used for exact matching. RESULTS: Based on the full optimal 1:1 
matching, only 40 of the 43 original depot initiators were matched to a corresponding 
oral initiator. After matching, there were no statistically signiﬁ cant differences between 
the depot and oral cohorts on any of the study entry covariates examined. During the 
12-month study, 20% of depot patients discontinued their initial medication, com-
pared with 40% of oral patients (survival curve comparison, p = 0.025; Hazard Ratio 
= 0.33 [0.12, 0.92], p = 0.033, NNT = 6 [3,-34]). No statistically signiﬁ cant differences 
were found between the two groups on other assessed outcomes, including hospitaliza-
tion, length of stay, and quality of life and disease severity measures. CONCLUSIONS: 
Systematic matching of patients initiated on depot with those initiated on oral anti-
psychotics showed that the oral-initiated patients were statistically signiﬁ cantly more 
likely to discontinue their medication. Findings highlight the importance of systematic 
matching of patient cohorts when comparing treatment outcomes in observational 
studies.
PMH3
DETERMINANTS OF PSYCHIATRIC HOSPITAL ADMISSION IN 
SCHIZOPHRENIA
Olfson M1, Marcus S2, Ascher-Svanum H3, Faries D3
1Columbia University Medical Center, New York, NY, USA; 2Penn Social Policy & Practice, 
Philadelphia, PA, USA; 3Eli Lilly & Company, Indianapolis, IN, USA
OBJECTIVES: Hospital admission is a common and costly event in schizophrenia. An 
analysis of phase 1/1A CATIE clinical trial data assessed various patient socio-demo-
graphic and clinical characteristics in relation to risk of psychiatric hospital admission. 
METHODS: We followed 1460 study participants from baseline until ﬁ rst schizophre-
nia-related hospital admission, study medication discontinuation, or 18 months. Step-
wise Cox regression models assessed the adjusted hazard ratio (AHR) of hospital 
admission by baseline patient socio-demographic and clinical characteristics. 
RESULTS: In 869 person-years of follow-up, 203 patients were hospitalized. The adjusted 
hazards of hospital admission were not signiﬁ cantly related to patient socio-demographic 
characteristics. Increased risk of admission was linked to early age (<17 years) of ﬁ rst 
antipsychotic treatment (AHR: 2.09; 95%CI: 1.45–3.02), psychiatric hospital admission 
in past year (AHR: 2.92; 95%CI: 2.18–3.90), and DSM-IV alcohol (AHR: 1.55; 95%CI: 
1.15–2.08) and drug (AHR: 1.50; 95%CI: 1.13–2.00) use disorders in the past 5 years. 
Severe (5–7) as compared with mild (1–3) baseline global clinical severity (AHR: 1.51; 
95%CI: 1.03–2.23) (CGI-I), high (>20) as compared with low (7–15) positive symptoms 
(AHR: 1.53; 95%CI: 1.08–2.16) (PANSS-positive subscale), and low (0–2.2) as compared 
with high (>3.1) social function (AHR: 1.47; 95%CI: 1.04–2.08) (Heinrichs-Carpenter 
QLI) were related to signiﬁ cantly increased risk of hospital admission. As compared with 
olanzapine treatment assignment, quetiapine (AHR: 2.12; 95%CI: 1.37–3.27), perphen-
azine (AHR: 1.64; 95%CI: 1.02–2.65), and ziprasidone (AHR: 2.67; 95%CI: 1.62–4.39), 
though not risperidone (AHR: 1.40; 95%CI: 0.89–2.21), were also associated with 
increased hospital admission risk. Self-rated physical health (SF-12 PCS) and drug attitudes 
(DAI) were not signiﬁ cantly related to risk. CONCLUSIONS: In the treatment of schizo-
phrenia, efforts to lower hospital admission risk should focus on patients with early 
onset disorders, recent inpatient admissions, severe positive symptoms, high global 
clinical severity, poor social function, and comorbid substance use disorders and should 
select an appropriate antipsychotic medication.
PMH4
A PHASE IV STUDY OF THE EFFECTIVENESS OF QUETIAPINE 
EXTENDED RELEASE 600 MG ONCE A DAY TO CONTROL THE 
SYMPTOMS OF MANIC PHASE OF BIPOLAR DISORDER: THE EMMY 
TRIAL
Segovia M1, Polanco AC1, Anaya P1, López RJ1, Gutiérrez D2
1AstraZeneca, Naucalpan, Mexico; 2National Institute of Psychiatry, D.F., Mexico
OBJECTIVES: To assess the efﬁ cacy of a 600 mg/day dose of Quetiapine Extended 
Release administrated once a day at evening as monotherapy or in combination with 
lithium or valproate for 21 days. METHODS: A multi-center phase IV study was 
designed to assess the efﬁ cacy of quetiapine extended release 600 mg per day either 
as monotherapy or combined therapy with lithium and valproic acid in the treatment 
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of patients with mania associated to Bipolar Disorder assessed by change in the Young 
Mania Rating Scale (YMRS) score and Clinical Global Impression (CGI) score from 
inclusion to day 21. Quality of life and safety/tolerability were measured with the 
Euro Quality of Life 5D (EQ5D), Work Productivity and Activity Impairment, Barnes 
Akathisia Rating Scale, Simpson-Angus Scale, physical examinations, adverse events, 
change of weight and other adverse events of special interest. The efﬁ cacy analysis 
was based on the modiﬁ ed intention-to-treat population, that included all patients 
who received study medication and who had a YMRS assessment at inclusion and at 
least one YMRS valid assessment after inclusion resulting in a total of 88 patients. 
RESULTS: YMRS total score reduction in 21 days was 20.55 points (95% CI, 
22.82–18.27); P < 0.0001. CGI total score decreased in 2.41 units, (95% CI, 2.69–
2.13); P < 0.0001. The EQ5D index increased 0.21 points (95% CI, 0.16–0.27) P < 
0.0001. The EQ5D Visual Analog Scale increased 23.49% (95% CI, 16.36%–
30.61%); P < 0.0001. CONCLUSIONS: Overall results shown in this study demon-
strate an improvement in the control of patients in maniac phase of bipolar disorder 
with an increase in Quality of Life.
PMH5
ESTABLISHING THE COMPARATIVE EFFICACY OF ALZHEIMER’S 
DISEASE THERAPY THROUGH SYSTEMATIC REVIEW AND 
COMPARATIVE ANALYSIS
Modha R1, Wieffer H2, Pietri G2, Pueschner F3, Gaudig M3
1Heron Evidence Development Ltd, London, UK; 2Heron Evidence Development Ltd, Luton, 
UK; 3Janssen-Cilag GmbH, Neuss, Germany
OBJECTIVES: For therapeutic augmentation of impaired cholinergic transmission in 
Alzheimer Disease (AD), Acetylcholine-Esterase-inhibitors (ACHE-I; galantamine, 
donepezil, rivastigmine) are approved therapies in mild to-moderate AD. The NMDA 
receptor partial antagonist (memantine) is licensed for therapy of moderate–severe 
AD. In order to inform clinical decision-making about efﬁ cacy, safety and broader 
non-cognitive outcomes, we identiﬁ ed evidence from comparative and non-compara-
tive studies. METHODS: A comprehensive search was conducted on Medline, 
Embase, conference abstracts and the Cochrane Library aimed to identify all ran-
domised, placebo controlled trials (RCTs) reporting efﬁ cacy and/or safety outcomes 
and randomised, controlled comparative trials. In a second step, trials with drug 
dosing outside the approved European Summary of Product Characteristics were 
excluded. Eligibility of trials was assessed by two blinded reviewers; quality of trials 
were assessed by CONSORT. Meta-analyses were performed, reporting ﬁ xed and 
random effects using comparative analytical techniques. RESULTS: Fifty—eight 
studies fulﬁ lled the inclusion criteria. In 45 trials, ACHE-I were tested against placebo, 
in 9 trials against another ACHE-I. For memantine, 9 placebo-controlled trials were 
identiﬁ ed. In most trials, patients were treated between 12–30 weeks; 9 RCTs reported 
longer-term outcomes, up to 24 months. After critical appraisal, 33 studies were 
included in further analyses. Meta-analysis of effects on cognition (ADAS-cog, MMSE, 
SIB) showed superiority of at least one ACHE-I versus placebo at the 3 months, 6 
months and longer-time timepoint. Results for memantine indicated non-signiﬁ cant 
improvement at any assessed timepoint. Behavioural outcomes were less well reported 
but showed superiority versus placebo for galantamine and memantine measured by 
the Neuropsychiatric Inventory Scale. CONCLUSIONS: There is abundant evidence 
for the efﬁ cacy, safety and tolerability of ACHE-Is in the treatment of patients with 
mild to moderate AD. Data for improved behavioural functioning is limited though 
available for galantamine and memantine.
PMH6
INCREASING ADMINISTRATIVE PREVALENCE OF ATTENTION-DEFICIT/
HYPERACTIVITY DISORDER (ADHD) IN GERMANY: EVIDENCE FROM 
NORDBADEN, 2003 TO 2008
Schlander M1, Schwarz O1, Trott GE1, Banaschewski T2, Scheller W3, Viapiano M4, 
Bonauer N4
1Institute for Innovation & Valuation in Health Care, Wiesbaden, Germany; 2University of 
Heidelberg, Mannheim, Germany; 3Verband der Ersatzkassen (vdek), Stuttgart, Germany; 4KV 
Baden-Wuerttemberg, Karlsruhe, Germany
BACKGROUND: In our age and gender speciﬁ c analyses for calendar year 2003, we 
observed an administrative prevalence rate of ADHD in Nordbaden (a region in the 
South-West of Germany with a population of >2.7 million) of 0.53%, with a peak 
among 9-year old boys at 8.43%. From 2003 to 2008, methylphenidate prescriptions 
(deﬁ ned daily doses, DDDs) in Germany increased 2.65-fold, raising concern about 
potentially inappropriate use. OBJECTIVES: To establish a longitudinal ADHD 
patient database and to assess changes of ADHD administrative prevalence rates by 
age and gender during the period from 2003 to 2008, in order to lay the foundation 
for further analyses of treatment and prescribing patterns. METHODS: The complete 
claims database of the organization of physicians registered with statutory health 
insurance [SHI] (Kassenaerztliche Vereinigung, KV) in Nordbaden/Germany was 
available for analysis, covering the total regional population enrolled in SHI (>2.2 
million). Age and gender speciﬁ c 1-year prevalence rates of ADHD were determined 
for years 2003 through 2008. RESULTS: During the 6-year period under study, the 
overall one-year ADHD prevalence rate increased from 0.53% to 0.90%. ADHD 
(hyperkinetic disorder: ICD-10, F90.0, F90.1) prevalence rates were highest in the age 
group 6–12 years (peak [2008] among nine-year-old children, 9,55%; boys, 12,31%), 
increasing continuously during the observation period (a) age group 6–12: from 
4.75% (boys, 6.91%; girls, 2.46%) to 7.62% (boys, 10.44%; girls, 4.66%); (b) age 
group 13–17: from 1.73% (boys, 2.66%; girls, 0.75%) to 3.78% (boys, 5.69%; girls, 
1.74%); adults (age >18 years): from 0.04% (males, 0.05%; females, 0.03%) to 
0.14% (males, 0.18%; females, 0.10%). CONCLUSIONS: German methylphenidate 
prescription growth outpaced the increase in ADHD diagnoses from 2003 to 2008. 
Further research seems warranted and has been initiated with regard to the underlying 
dynamics of physician group involvement, coexisting conditions, utilization patterns 
(treatment duration, intensity, switches), and regarding economic implications.
PMH7
USING DRUG DISPENSING DATA TO STUDY THE VALIDITY OF 
PARASKAVEDEKATRIAPHOBIA
Pechlivanoglou P, Rozenbaum MH, Le HH, Postma MJ, Vegter S
University of Groningen, Groningen, The Netherlands
OBJECTIVES: From tales of Christian tradition to essays of 17th century physicians, 
Friday has been identiﬁ ed as a day of ill luck. Amongst all Fridays of the year however 
the one coinciding with the 13th day of the month is known to be associated with 
extreme misfortune. Therefore, the fate of persons born on Friday the 13th (F13) 
warrants investigation. We investigated the effect of being born on Friday the 13th 
on the prevalence of a) cancer; b) diabetes; c) mental health disorders; and d) sexual 
disorders. METHODS: Persons born on Friday the 13th were identiﬁ ed from a drug 
utilization database. To control for seasonal variation and time-trends, persons born 
on Friday the 6th and Friday the 20th were selected as controls. Differences in pre-
scription prevalences were analyzed using multivariate logistic regression. RESULTS: 
A total of 4202 cases and 8987 controls were identiﬁ ed. The number of cases was less 
than expected based on the number of controls (expected number 4396, P < 0.01), 
suggesting a survival disadvantage for F13 cases. Age (32.8 ± 22.6 vs. 32.7 ± 23.0) 
and gender (53.1% vs. 53.3% female) were similar. Multivariable logistic regression 
showed no increase in prescription prevalences for F13 cases (P > 0.1 for all drug 
classes). Exploratory analyses showed that F13 cases being prescribed antipsychotics 
were younger than controls (P = 0.03) and diabetic cases were more often male (P = 
0.04). CONCLUSIONS: Although attenuating effects of survivor selection bias cannot 
be ruled out, the current study found no scientiﬁ c basis for paraskavedekatriaphobia 
in relation to drug utilization. Signiﬁ cant differences in age and gender for speciﬁ c 
subgroups may be attributed to the multiple comparison issue. Results will be pre-
sented on interaction effects of Friday the 13th coinciding with full-moon (n = 154) 
and good Friday (n = 113).
PMH8
EXCESS MORTALITY RISK IN PATIENTS WITH PSYCHOSIS 
HOSPITALIZED IN JAPANESE NATIONAL MENTAL HOSPITALS
Inagaki A1, Nakagawa A2, Fuwano S3, Itoh T4, Tsukada K4, Urata J5
1Keio University, Fujisawa, Kanagawa, Japan; 2National Center of Neurology and Psychiatry, 
Kodaira, Tokyo, Japan; 3Fuwano Clinic, Jouetsu, Niigata, Japan; 4Kohnodai Hospital, 
International Medical Center, Ichikawa, Chiba, Japan; 5Sakuragaoka Memorial Hospital, Tama, 
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OBJECTIVES: To examine the standardized mortality ratio (SMR) in inpatients with 
schizophrenia and related psychosis. METHODS: To compare the mortality risk in 
Japanese with psychosis with that of the general population, we utilized two large 
studies, called “the JESS2000” and “the JESS2000 Follow-up Study.” In the JESS2000 
study, 2,309 psychotic patients who had been hospitalized in Japanese national mental 
hospitals as of September 1, 2000 were included. In the JESS2000 Follow-up Study, 
the JESS2000 patients were followed up and those who had died as of September 1, 
2005 were identiﬁ ed retrospectively. The expected number of deaths was calculated 
by multiplying the number of patients in each gender- and age-speciﬁ c subgroup by 
the mortality rate derived from the Japanese abridged life table and adding all of the 
ﬁ gures in each of these subgroups. The SMR was calculated by the observed number 
of deaths, identiﬁ ed in the JESS2000 Follow-up Study, divided by the expected 
number. RESULTS: Of 2309 original samples, 56.3% were male. On September 1, 
2000, the mean age (SD) was 52.0 (14.6) years. The mean duration of hospitalization 
was 10.3 (12.0) years. The mean age at onset of psychosis was 23.7 (7.9) years. The 
deaths of 204 patients were conﬁ rmed as of September 1, 2005. Of these 204 deceased 
patients, 13 committed suicide, 6 died from accidents and 148 died of natural causes. 
No information regarding cause of death for the remaining 16 patients could be 
obtained. The expected numbers of deaths in this cohort was 100.67. Therefore the 
SMR for all causes in this cohort was estimated at 2.03 or more. CONCLUSIONS: 
Our ﬁ ndings were similar to the results of the systematic review by Saha et al., which 
reported the SMR for schizophrenia as 2.58. 
MENTAL HEALTH – Cost Studies
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BUDGET IMPACT ANALYSIS OF SERTINDOLE IN THE TREATMENT OF 
SCHIZOPHRENIA IN POLAND
Walczak J, Augusty ska J, Sołtys E, Nogas G
Arcana Institute, Cracow, Poland
OBJECTIVES: To evaluate the ﬁ nancial consequences of sertindole reimbursement for 
the Polish National Health Fund (NHF) budget. METHODS: Budget impact analysis 
was performed in a 3-year time horizon from two perspectives of NHF and a patient. 
Costs of oral antipsychotic drugs and EKG test of patients treated with sertindole were 
included. Two future scenarios were estimated: 1) with reimbursement of sertindole, 
and 2) without sertindole reimbursement. Target population was estimated using 
